Board
Screen
Heat
Cal
Watch
News
Blog
TV
Home
/
MRNA
Home
/
MRNA

NASDAQ
$245.307
$245.307

Overview

Price performance
Low
$230.21
High
$253.72
Market open. Last updated: Nov 4, 2026, 7:07 PM UTC
$
245.31
16.87 (7.38%)
Average, 50 days
$185.79
$88.42
Open
$235.49
Previous close
$228.44
52-week high
$254.48
Oct 21, 2026 (15 days ago)
52-week low
$22.28
Nov 21, 2025 (1 year ago)
1001.02%

Valuation & Estimates

Earnings

Financials

Insider Trading

Peer Analysis

Insights & Activity

Market Cap
97.94B
Volume
8 953 725
Total Return (3M)
330.12%
Total Return (1Y)
932.11%
69.67
Sector
Healthcare
Links
Tags
Healthcare
Biotechnology
NASDAQ
US
Website
modernatx.com
Socials
About
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.

Frequently asked questions

MRNA · Moderna, Inc.

01What is Moderna, Inc. stock price today?

The current price of MRNA is $245.31 — it has increased by 7.38% since the previous close. Data as of Nov 4, 2026.

02Is Moderna, Inc. stock price growing?

MRNA is up 11.15% over the past week, up 29.01% over the past month and up 932.11% over the past year. The price is above its 200-day moving average of $88.42.

03What do analysts say about MRNA stock?

Of the 23 analysts covering Moderna, Inc., 1 rates it a strong buy, 3 rate it a buy, 15 rate it a hold, 2 rate it a sell and 2 rate it a strong sell. The overall consensus is neutral. Analyst ratings are opinions and do not guarantee future performance.

04What is Moderna, Inc. market cap?

Moderna, Inc. has a market capitalization of $97.94B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

05What were Moderna, Inc. earnings last quarter?

In its most recent quarterly report, Moderna, Inc. posted a loss of $1.97 per share against an estimate of -$2.03, beating expectations by 2.96%. Upcoming reports are listed in the earnings calendar.

06What is Moderna, Inc. revenue for the last quarter?

Moderna, Inc. reported revenue of $145M in its most recent quarter, which has increased by 2.11% compared with the same quarter a year earlier. Analysts had expected $102.93M.

07Does Moderna, Inc. pay dividends?

Moderna, Inc. has not paid any dividends over the past year.

08Who are Moderna, Inc. competitors?

Companies most comparable to Moderna, Inc. include Pfizer Inc., GSK plc, BioNTech SE, Vaxcyte, Inc. and Vir Biotechnology, Inc.

09How volatile is MRNA stock?

In the latest trading session MRNA moved between $230.21 and $253.72, a range of 9.58% of its current price.

10Should I invest in Moderna, Inc. stock?

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Moderna, Inc. shows a strong buy rating today. Technical ratings are indicators, not investment advice.

11What are MRNA stock 52-week high and low?

Over the past 52 weeks MRNA has traded between $22.28 and $254.48. The current price is 3.60% below its 52-week high.

Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.